Categories
Uncategorized

Chronic lymphocytic leukemia management

Management goals are to eliminate chemoimmunotherapy treatments and replace it with more effective combinations of small molecules inhibitors, to get a deep remission as possible, increase complete remission with undetectable minimal residual disease with well tolerated non-chemo immunotherapy treatment, to improve and lengthen both progression free survival and overall survival, and promote immune reconstitution.

Recent studies show there is an improved progressive free survival with BTK inhibitor-based therapy over chemoimmunotherapy

BCL – 2 inhibitors – Venetoclax, induce deeper remissions in CLL than BTK inhibitors.

Management goals are to eliminate chemoimmunotherapy treatments and replace it with more effective combinations of small molecule inhibitors, to get a deep remission as possible, increase complete remission with undetectable minimal residual disease (MRD) with well tolerated non-chemo immunotherapy treatment, to improve and lengthen both progression free survival and overall survival, and promote immune reconstitution.

First line treatments include fixed duration chemoimmunotherapy, a continuous Bruton tyrosine kinase inhibitor, the time-limited B-cell lymphoma 2 inhibitor venetoclax plus anti- CD 20 anybody obinttuzumab and BTK inhibitor plus venetoclax and a combination of venetoclax, obinutuzumab or Rituximab.

The combination of venetoclax-obinutuzumab with or without Ibrutinib lead to longer and deeper responses than the current first line chemoimmunotherapiesFludarabine/Cyclophosphamide/Rituximab or bndamustine/Rituximab: at 15 months, the percentage of patients with undetectable minimal residual disease with venetoclax- obintizumab was 86.5% and the Venetoclax-obinutuzumab/Ibrutinib group was 92.2%, while the chemo immunotherapy group was 52%.

 

BTK inhibitors have revolutionized the treatment of CLL shielding significant improvements in efficacy outcomes versus traditional therapy:Ibrutinib, zanubrutinib, Pirtobrutinib,

Acalabrutinib plus Obinutuzumab have a progression free survival of 72 months.

Lisocabtagene maraleucil CD 19:CAR-T therapy in heavily pretreated patients with CR rate of 20%.

 

Leave a Reply

Your email address will not be published. Required fields are marked *